EN DE
Watch ENvue Medical Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ENvue Medical Inc. (FEED) fair value: what the stock is really worth

As of Oct 29, 2026: fair value (intrinsic value) of ENvue Medical Inc. stock $0.03, price $0.22, upside -86.4%, quality 26 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EM ENvue Medical Inc. logo Thin data Oct 30, 2026

ENvue Medical Inc.

FEED · US
Very expensive, weak quality

Our calculation puts a fair price 86% below what the stock costs today.

Expensive Growth (revenue 5y +32.6 %/yr in USD)
Revenue last quarter 52% below a year ago.
Fair value $0.0300 · Strongly overvalued (−86.4%)
Quality 26/100
Negative free cash flow
Trails peers (1/6)
Narrow moat 5/100 · thin data
Thin data
Watch ENvue Medical Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$88,968 $0.1819 Fair Value $0.0300 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.

How to read this chart

60‑month range $0.1819 – $88,968 · fair‑value band $0.0200 – $0.0400 · the $0.2200 price screens above the $0.0300 fair value. As of Oct 30, 2026.

Follow ENvue Medical in your weekly email

Every Wednesday you see whether ENvue Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance.

Show moreShow less

Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.

The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.

The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. The company was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025.

The company was incorporated in 2003 and is based in Tyler, Texas.

Stock analysis

ENvue Medical Inc. (FEED) currently trades at $0.2200, while our model-based Fair Value estimate is $0.0300, 86.4% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.0200 (bear) to $0.0400 (bull), the price of $0.2200 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

ENvue Medical Inc. reported revenue of $2.6M in FY2025 versus $1.7M in FY2021, a compound +10.8%/yr. Reported net income was −$18.2M in FY2025.

Key figures

Market cap $231K Micro · P/S ratio 0.12 · EPS (TTM) $−339.36 · Return on equity −59.1% · Return on assets (EBIT) −66.0% · Operating margin −2,290% · Revenue (TTM) $1.9M · Revenue growth (YoY) −51.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 100% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −86%, FEED screens richer than that median.

Fair Value models

Bear $0.0200 Fair Value $0.0300 Bull $0.0400
Price $0.2200 · Upside -86.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.0200 $0.0300 $0.0400 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.0200 $0.0300 $0.0400 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 23
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 14
How calm the share price moves, does not count
Momentum 0
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−0.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+50.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.6%
Start year 2020 (pandemic). Over 10 years: +33.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−757.5% (2020) → −459.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

FEED screens overvalued: fair value 86% below the price. Compare with Abbott Laboratories, →

Earlier news

News mood ⓘNews mood, the average tone of recent news (14 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare ENvue Medical Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 327 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −86.4% · Bottom 25%
Profitability
Return on assets −44.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −51.6% · Bottom 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/S (12 months) 0.12× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $306.13 $336.74 +10% vs FEED
Boston Scientific Corporation BSX $42.43 $46.67 +10% vs FEED
DexCom, Inc DXCM $78.56 $86.42 +10% vs FEED
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥175.30 ¥192.83 +10% vs FEED
GE HealthCare Technologies Inc GEHC $75.82 $69.99 −8% vs FEED
Edwards Lifesciences Corporation EW $90.56 $82.04 −9% vs FEED
Siemens Healthineers AG SHL €41.87 €35.21 −16% vs FEED
Abbott Laboratories, ABT $103.10 $75.28 −27% vs FEED
Medtronic plc MDT $94.79 $65.61 −31% vs FEED
Koninklijke Philips N.V PHIA €23.78 €15.23 −36% vs FEED

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ENvue Medical Inc. · Fair Value
$0.0300 −86%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "ENvue Medical Inc. Fair Value". https://www.fairvalue-calculator.com/stock/FEED

Frequently asked questions

Is ENvue Medical Inc. (FEED) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of $0.0300 versus a price of $0.2200, about −86% upside (overvalued).
What is the fair value of FEED?
Our model-based fair value for ENvue Medical Inc. is $0.0300 (as of Oct 30, 2026), built from audited fundamentals. The current price: $0.2200.
What is the quality score of FEED?
ENvue Medical Inc. has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ENvue Medical Inc. (FEED)?
Our model-based price target is the fair value of $0.0300 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario $0.0200, optimistic scenario $0.0400. It is a calculation from audited fundamentals, not an analyst target.
What is the ENvue Medical Inc. stock forecast for 2026?
Our models put fair value at $0.0300, about −86% upside versus a price of $0.2200 (overvalued). Cautious scenario $0.0200, optimistic scenario $0.0400. The calculation is refreshed regularly with new filings.
What is the revenue of ENvue Medical Inc. (FEED)?
ENvue Medical Inc. reported trailing-twelve-month revenue of about $1.9M (latest available figure, as of Oct 30, 2026).
What is the intrinsic value of ENvue Medical Inc. (FEED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ENvue Medical Inc. it is $0.0300 per share (as of Oct 30, 2026), against a price of $0.2200. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ENvue Medical Inc. stock overvalued or undervalued in 2026?
As of Oct 30, 2026, FEED trades above its calculated fair value: price $0.2200, fair value $0.0300, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FEED?
No. The price is what the market pays today ($0.2200); the fair value is what the company's own numbers justify ($0.0300). For ENvue Medical Inc. the two are $0.1900 per share apart. That gap is exactly why we show both numbers side by side.
How much is ENvue Medical Inc. worth?
The market values ENvue Medical Inc. at about $231K (market capitalisation, as of Oct 30, 2026). Per share that is $0.2200; our models calculate a fair value of $0.0300 per share.
What do the bullish and bearish scenarios say about FEED?
Our models span a range for ENvue Medical Inc.: cautious scenario $0.0200, base $0.0300, optimistic $0.0400 per share (as of Oct 30, 2026, price $0.2200). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ENvue Medical Inc. (FEED)?
Balance-sheet figures for ENvue Medical Inc. (as of Oct 30, 2026): return on equity −59.1%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is FEED from its 52-week high?
ENvue Medical Inc. trades at $0.2200, about 100% below its 52-week high of $66.84 and at the low of $0.2200 (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0300 is for.
Which stocks are comparable to ENvue Medical Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ENvue Medical Inc. stock attractive at the current price?
The data as of Oct 30, 2026: price $0.2200, calculated fair value $0.0300 (−86%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FEED calculated?
We run ENvue Medical Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. ENvue Medical Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ENvue Medical Inc. (FEED)?
The closing price on Oct 29, 2026 was $0.2200. Our model-based fair value is $0.0300, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ENvue Medical Inc. right now?
The price sits above even our optimistic bull case ($0.0400). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.0200 to $0.0400) leaves room in how you read the outcome.

Key figures of ENvue Medical Inc.

How large is the market capitalisation of ENvue Medical Inc. (FEED)?
The market capitalisation of ENvue Medical Inc. is $231K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ENvue Medical Inc. (FEED)?
The price-to-sales ratio of ENvue Medical Inc. is 0.12 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ENvue Medical Inc. (FEED)?
Earnings per share at ENvue Medical Inc. are $−339.36. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ENvue Medical Inc. (FEED)?
The return on equity (ROE) of ENvue Medical Inc. is −59.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ENvue Medical Inc. (FEED)?
On an EBIT basis the return on assets of ENvue Medical Inc. is −66.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ENvue Medical Inc. (FEED)?
The operating margin of ENvue Medical Inc. is −2,290% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ENvue Medical Inc. (FEED)?
Revenue at ENvue Medical Inc. is growing −51.6% versus a year earlier (3y avg +50.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ENvue Medical Inc. (FEED) generate?
The free cash flow of ENvue Medical Inc. is −$9.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ENvue Medical Inc. (FEED) hold?
ENvue Medical Inc. holds more cash than debt, $3.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch ENvue Medical Inc. in the live analysis

One click puts ENvue Medical Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.